Clarus Therapeutics Holdings Overview

Clarus Therapeutics Holdings Cost of Revenue

Cost of Revenue analysis for CRXT.

Quarterly Cost of Revenue

$1.16M

↑ 109.39% YoY

As of Jun 30, 2022

Annual Cost of Revenue (TTM)

$3.99M

↑ 391.99% YoY

Trailing 12 months ending Jun 30, 2022

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin